Skip to main content

An innovative, effective and minimally-invasive retinal cell therapy combined with a new injection system for treatment of retinal degenerative diseases.

Descripción del proyecto

Revolutionary drug and cell delivery system could improve vision for millions

The retina is an amazing tissue on the inside back wall of the ocular chamber. Its millions of light-sensitive photoreceptors and other cells convert wavelengths of light into neuronal signals that are sent via the optic nerve to the brain where they are perceived as visual images. Degeneration of the retina affects millions - and there is no cure. Some treatments can slow the progress, but they can be associated with suboptimal efficacy, serious complications and side effects. The Israeli SME Everads Therapy Ltd has developed a revolutionary drug and cell delivery system for delivering injectable therapies to the back of the eye. With the goal of overcoming significant challenges in current treatment methodologies for retinal diseases, Everads' platform access method and delivery system offer the promise of improving the efficacy and safety of drug therapies while improving patient compliance and outcomes. The safe, effective, and minimally invasive delivery system is being optimised and the market and business strategy developed with EU-funding of the EIS project.

Ámbito científico

  • /ciencias médicas y de la salud/medicina clínica/trasplante
  • /ciencias médicas y de la salud/biotecnología médica/tecnologías celulares
  • /ciencias sociales/economía y empresa/gestión y empresas/comercio
  • /ciencias médicas y de la salud/medicina clínica/oftalmología/glaucoma

Convocatoria de propuestas

H2020-SMEInst-2018-2020-1
Consulte otros proyectos de esta convocatoria

Régimen de financiación

SME-1 - SME instrument phase 1

Coordinador

EVERADS THERAPY LTD
Dirección
27 Habarzel Street Migdalei Orr Building A 5Th Flo
Tel Aviv
Israel
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Aportación de la UE
€ 50 000